43 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
and related process expenses includes third party direct manufacturing costs, quality control testing and packaging costs. In Q1 2024, manufacturing
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring … of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product Candidate … ) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
expense.
Manufacturing and related process expenses includes third party direct manufacturing costs, quality control testing and packaging costs. In Q3 … and packaging costs. YTD Q3 2023 manufacturing costs primarily related to the Company's oxypurinol quality control and stability related costs as compared
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
.
Manufacturing and related process expenses includes third party direct manufacturing costs, quality control testing and packaging costs. In Q1 2024
424B3
dwe035jlqw
13 Jun 24
Prospectus supplement
4:11pm
424B3
yzyhtbfi8r
13 Jun 24
Prospectus supplement
4:10pm
424B3
2upt9 w13
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
b8ne g9krpg2a
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
hq6b4u5a80js2hat313
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
6-K
EX-99.2
j4luysr0n6dshqiq8q
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
ktd3c 5q9y25qx5bk5mi
25 Aug 23
Prospectus supplement
6:00am
424B3
tyalps 44jb
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
0i4andpui8oc9
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.2
be395 q23b990
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.2
fc5k9rrqb
3 Apr 23
Consolidated Financial Statements
6:05am